

Updated 05/19/2026

Click on the link below to be directed to study information at "ClinicalTrials.Gov" the US National Institutes of Health website.

Condition

Active Research Studies

St. Luke's Contact

***HEART STUDIES***

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)	<a href="#"><u><b>A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor X1a Inhibitor, After a Recent Acute Coronary Syndrome</b></u></a>	Kayla W. RN 218-249-6069 Charity G. RN 218-249-5177 <a href="mailto:ASL-Whiteside@aspirus.org"><u>ASL-Whiteside@aspirus.org</u></a>
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE-2)	<a href="#"><u><b>Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)</b></u></a>	Kayla W. RN 218-249-6069 Charity G. RN 218-249-5177 <a href="mailto:ASL-Whiteside@aspirus.org"><u>ASL-Whiteside@aspirus.org</u></a>
Evaluation of inclisiran versus placebo for the prevention of major adverse cardiovascular and limb events in patients undergoing percutaneous coronary intervention or peripheral endovascular intervention (VICTORION-INTERVENTION)	<a href="#"><u><b>A pragmatic double-blind, placebo-controlled, multicenter Phase 4 trial designed to assess the superiority of inclisiran vs. placebo on preventing major adverse cardiovascular and limb events.</b></u></a>	Kayla W. RN 218-249-6069 Charity G. RN 218-249-5177 <a href="mailto:ASL-Whiteside@aspirus.org"><u>ASL-Whiteside@aspirus.org</u></a>